Establishing the characteristics of cell models is a key component of assay optimization processes performed at AstraZeneca. Learn how to use longitudinal live-cell imaging assays to characterize cells for assay development and assay endpoints. Examples will include how to measure cell confluence and assess the proliferation rate of different cell types to establish optimal assay conditions to screen for cytostatic or cytotoxic compounds in cancer cell lines.
In addition to the analysis of cell phenotype using imaging platforms, advanced high throughput flow cytometry is also being used to gain insights into cell behavior, especially in the immuno-oncology field. Harnessing the immune system to combat cancer is a key interest area for AstraZeneca, and characterizing treatment effects upon the immune cell phenotype is a key piece of data in drug discovery workflows. Learn how advanced high throughput flow cytometry is being used to enable rapid analysis of cells and beads to measure cytokine levels, cell proliferation, and cytolytic activity of primary human immune cells.
Key webinar discussion topics include:
- cell proliferation, confluence and transfection efficiency using longitudinal live-cell imaging.
- cytokine release, proliferation and cytolytic activity of immune cells using advanced high throughput flow cytometry.
About the speaker
Dr. David Baker
Senior Research Scientist
David Baker, Ph.D. has worked at AstraZeneca for three years following his Ph.D. in cellular neuroscience at the University of Sheffield. David works within the Cellular Assay Development group within Discovery Biology, where his main role is to develop assays for oncology and neuroscience drug discovery projects that enable screening of hundreds to millions of compounds. In addition to the development of plate-based and high-content cellular assays, David has been heavily involved in setting up the immuno-oncology capability utilizing advanced high throughput flow cytometry, developing assays to look at T cell proliferation, activation and killing for use in AstraZeneca’s immuno-oncology projects.